February 8, 2013—Hospitals that use 340B covered outpatient drugs in departments that treat both inpatients and outpatients cannot buy drugs for such units at group purchasing organization (GPO) prices and then replenish their inventories with drugs bought at 340B prices, the Health Resources and Services Administration (HRSA) said yesterday.
Hospitals have used this drug-purchasing model in so-called “mixed-use” settings such as emergency, surgical, and radiology departments for many years and its invalidation by HRSA’s Office of Pharmacy Affairs (OPA) is expected to cause considerable disruption.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)